Dagracycline is a tetracycline antibiotic that fights bacteria in the body.
Dagracycline is used to treat many different bacterial infections, such as acne, urinary tract infections, intestinal infections, eye infections, gonorrhea, chlamydia, periodontitis (gum disease), and others.
Dagracycline is also used to treat blemishes, bumps, and acne-like lesions caused by rosacea. Dagracycline will not treat facial redness caused by rosacea.
Some forms of Dagracycline are used to prevent malaria, to treat anthrax, or to treat infections caused by mites, ticks, or lice.
Dagracycline may also be used for purposes not listed in this medication guide.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
Dagracycline® and Dagracycline® CAP are indicated for treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox, and tick fevers caused by Rickettsiae.
Sexually Transmitted Infections
Dagracycline and Dagracycline CAP are indicated for treatment of the following sexually transmitted infections:
Uncomplicated urethral, endocervical or rectal infections caused by Chlamydia trachomatis.
Nongonococcal urethritis caused by Ureaplasma urealyticum.
Lymphogranuloma venereum caused by Chlamydia trachomatis.
Granuloma inguinale caused by Klebsiella granulomatis.
Uncomplicated gonorrhea caused by Neisseria gonorrhoeae.
Chancroid caused by Haemophilus ducreyi.
Respiratory Tract Infections
Dagracycline and Dagracycline CAP are indicated for treatment of the following respiratory tract infections:
Respiratory tract infections caused by Mycoplasma pneumoniae.
Psittacosis (ornithosis) caused by Chlamydophila psittaci.
Because many strains of the following groups of microorganisms have been shown to be resistant to Dagracycline, culture and susceptibility testing are recommended.
Dagracycline is indicated for treatment of infections caused by the following microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug:
Respiratory tract infections caused by Haemophilus influenzae.
Respiratory tract infections caused by Klebsiella species.
Upper respiratory infections caused by Streptococcus pneumoniae.
Specific Bacterial Infections
Dagracycline and Dagracycline CAP are indicated for treatment of the following specific bacterial infections:
Relapsing fever due to Borrelia recurrentis.
Plague due to Yersinia pestis.
Tularemia due to Francisella tularensis.
Cholera caused by Vibrio cholerae.
Campylobacter fetus infections caused by Campylobacter fetus.
Brucellosis due to Brucella species (in conjunction with streptomycin).
Bartonellosis due to Bartonella bacilliformis.
Because many strains of the following groups of microorganisms have been shown to be resistant to Dagracycline, culture and susceptibility testing are recommended.
Dagracycline and Dagracycline CAP are indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug:
Urinary tract infections caused by Klebsiella species.
Dagracycline and Dagracycline CAP are indicated for treatment of the following ophthalmic infections:
Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence.
Inclusion conjunctivitis caused by Chlamydia trachomatis.
Anthrax Including Inhalational Anthrax (Post-Exposure)
Dagracycline and Dagracycline CAP are indicated for the treatment of Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.
Alternative Treatment for Selected Infections when Penicillin is Contraindicated
Dagracycline and Dagracycline CAP are indicted as an alternative treatment for the following selected infections when penicillin is contraindicated:
Syphilis caused by Treponema pallidum.
Yaws caused by Treponema pallidum subspecies pertenue.
Listeriosis due to Listeria monocytogenes.
Vincent’s infection caused by Fusobacterium fusiforme.
Actinomycosis caused by Actinomyces israelii.
Infections caused by Clostridium species.
Adjunctive Therapy for Acute Intestinal Amebiasis and Severe Acne
In acute intestinal amebiasis, Dagracycline and Dagracycline CAP may be a useful adjunct to amebicides.
In severe acne, Dagracycline and Dagracycline CAP may be useful adjunctive therapy.
Prophylaxis of Malaria
Dagracycline and Dagracycline CAP are indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (less than 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Dagracycline and Dagracycline CAP and other antibacterial drugs, Dagracycline and Dagracycline CAP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
How should I use Dagracycline?
Use Dagracycline kit as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Dagracycline kit kit contains antibiotic capsules, eyelid cleansing pads, and a moisturizing spray.
To use the eyelid cleansing pad:
Remove contact lenses before you use Dagracycline kit.
Wash your hands before using Dagracycline kit. Close the eyes and gently cleanse the eyelids using side to side strokes. Avoid touching the eyes directly. Rinse or leave on as directed by your doctor. Discard after use.
To use the moisturizing spray:
Hold the spray tip 4 to 6 inches away from the eye. Close the eye and spray directly onto the eyelid surface. Gently massage into the eyelids and lashes. If directed to do so by your doctor, repeat this procedure with the other eye.
If you prefer, you may spray onto the inner side of the finger and then gently massage onto the eyelids and lashes. Do not spray directly into the eyes.
To take the antibiotic:
Take Dagracycline kit by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.
Take Dagracycline kit with a full glass of water (8 oz/240 mL) and drink plenty of fluids to prevent ulcers and reduce throat irritation.
Do not eat or drink calcium-rich foods (eg, milk or other dairy products, calcium-enriched juices), or take an antacid that has aluminum, calcium, or magnesium in it; bismuth subsalicylate; iron; or urinary alkalinizers (eg, sodium bicarbonate) within 2 hours before or 2 hours after you take Dagracycline kit.
Use Dagracycline kit on a regular schedule to get the most benefit from it. It may take several days to see the full effect of Dagracycline kit.
To clear up your infection completely, take Dagracycline kit for the full course of treatment. Keep taking it even if your condition improves in a few days.
Do not use Dagracycline kit if it is past the expiration date on the bottle.
If you miss a dose of Dagracycline kit, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Dagracycline kit.
Uses of Dagracycline in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
Use: Labeled Indications
Acne: Adjunctive therapy in severe acne.
Actinomycosis: Treatment of actinomycosis caused by Actinomyces israelii when penicillin is contraindicated.
Acute intestinal amebiasis: Adjunct to amebicides in acute intestinal amebiasis.
Anthrax, including inhalational anthrax (postexposure): Treatment of anthrax caused by Bacillus anthracis, including inhalational (postexposure) prophylaxis; to reduce the incidence or progression of disease following exposure to aerosolized B. anthracis.
Cholera: Treatment of cholera infections caused by Vibrio cholerae.
Clostridium: Treatment of infections caused by Clostridium spp. when penicillin is contraindicated.
Gram-negative infections: Treatment of infections caused by Escherichia coli, Enterobacter aerogenes, Shigella spp., Acinetobacter spp., Klebsiella spp. (respiratory and urinary infections), and Bacteroides spp.; Neisseria meningitidis (when penicillin is contraindicated).
Gram-positive infections: Treatment of infections caused by Streptococcus spp., when susceptible.
Listeriosis: Treatment of listeriosis due to Listeria monocytogenes when penicillin is contraindicated.
Malaria prophylaxis: Prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (under 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine-resistant strains.
Mycoplasma pneumoniae: Treatment of infections caused by Mycoplasma pneumoniae.
Treatment of inclusion conjunctivitis or trachoma caused by Chlamydia trachomatis.
Periodontitis (20 mg tablet and capsule [Periostat (Canadian product)] only): Adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis.
Relapsing fever: Treatment of relapsing fever caused by Borrelia recurrentis.
Respiratory tract infections: Treatment of respiratory infections caused by Haemophilus influenzae, Klebsiella spp., or Mycoplasma pneumoniae; treatment of upper respiratory tract infections caused by Streptococcus pneumoniae; respiratory infections caused by Staphylococcus aureus (Dagracycline is not the drug of choice in the treatment of any type of staphylococcal infection).
Rickettsial infections: Treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae.
Rosacea (Oracea, Apprilon [Canadian product] only): Treatment of only inflammatory lesions (papules and pustules) of rosacea in adults.
Sexually transmitted infections: Treatment of lymphogranuloma venereum and uncomplicated urethral, endocervical, or rectal infections caused by Chlamydia trachomatis; granuloma inguinale (donovanosis) caused by Klebsiella granulomatis; chancroid caused by Haemophilus ducreyi; nongonococcal urethritis caused by Ureaplasma urealyticum; when penicillin is contraindicated, uncomplicated gonorrhea caused by Neisseria gonorrhea and syphilis caused by Treponema pallidum.
Note: The CDC sexually transmitted disease guidelines recommend dual antimicrobial therapy be used for uncomplicated gonorrhea due to N. gonorrhea resistance concerns; ceftriaxone is the preferred cephalosporin and Dagracycline is an alternative option for the second antimicrobial only in cases of azithromycin allergy (CDC [Workowski 2015]).
Skin and skin structure infections (Avidoxy only): Treatment of skin and skin structure infections caused by Staphylococcus aureus (Dagracycline is not the drug of choice in the treatment of any type of staphylococcal infection).
Vincent infection: Treatment of Vincent infection caused by Fusobacterium fusiforme when penicillin is contraindicated.
Yaws: Treatment of yaws caused by Treponema pallidum subspecies pertenue when penicillin is contraindicated.
Zoonotic infections: Treatment of psittacosis (ornithosis) caused by Chlamydophila psittaci; plague due to Yersinia pestis; tularemia caused by Francisella tularensis; brucellosis caused by Brucella spp. (in conjunction with streptomycin); bartonellosis caused by Bartonella bacilliformis; infections caused by Campylobacter fetus.
Off Label Uses
Anaplasmosis and ehrlichiosis
Based on the IDSA guidelines for the clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis (HGA) and babesiosis and the Centers for Disease Control and Prevention (CDC) guideline for the diagnosis and management of tickborne rickettsial diseases, Dagracycline is effective and recommended for the treatment of human anaplasmosis (also known as HGA) and human ehrlichiosis.
Bartonella infections in HIV-infected patients
Based on the US Department of Health and Human Services (HHS) guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents, Dagracycline is a recommended and effective agent for treatment of bacillary angiomatosis, peliosis hepatis, bacteremia, osteomyelitis, CNS infections, infective endocarditis, and other severe infections due to Bartonella in adolescent and adult HIV-infected patients.
Bite wound infection (animal or human bite)
Based on the IDSA guidelines for the diagnosis and management of SSTIs, Dagracycline is an acceptable alternative agent for the prophylaxis and treatment of bite wounds (animal or human).
Cellulitis, mild to moderate
Based on the Infectious Diseases Society of America (IDSA) guidelines for the diagnosis and management of skin and soft tissue infections (SSTIs) and the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections, Dagracycline is an effective and recommended treatment option for SSTIs caused by MRSA, particularly purulent cellulitis due to community-acquired MRSA (CA-MRSA).
Data from a randomized, double-blind, placebo-controlled trial support the use of Dagracycline in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD).
Based on the American College of Chest Physicians diagnosis and management of lung cancer clinical practice guidelines, intrapleural Dagracycline is effective and recommended in the management of recurrent, symptomatic, malignant pleural effusions.
Proctitis, acute or proctocolitis
Based on the CDC sexually transmitted diseases treatment guidelines, Dagracycline in combination with ceftriaxone is an effective and recommended agent in the treatment of acute proctitis or proctocolitis.
Prosthetic joint infection
Based on the IDSA guidelines for the management of prosthetic joint infection, Dagracycline is an effective and recommended agent for treatment (oral phase) of prosthetic joint infection and for chronic oral antimicrobial suppression of prosthetic joint infection due to staphylococci or Cutibacterium acnes.
Surgical prophylaxis, uterine evacuation (induced abortion or pregnancy loss)
Based on the American College of Obstetricians and Gynecologists guidelines for prevention of infection after gynecologic procedures, Dagracycline is effective and recommended as antimicrobial prophylaxis for uterine evacuation procedures for induced abortion or pregnancy loss.
Dagracycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline and is available as Dagracycline monohydrate and Dagracycline hyclate (hydrochloride hemiethanolate hemihydrate). The chemical designation of this light-yellow crystalline powder is α-6-deoxy-5-oxytetracycline. Dagracycline has a high degree of lipoid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Dagracycline will not degrade into an epianhydro form.
The molecular formula for Dagracycline hydrochloride hemiethanolate hemihydrate is (C22H24N2O8·HCl)2·C2H6O·H2O and the molecular weight is 1025.89. Dagracycline is a light-yellow crystalline powder. Dagracycline hyclate is soluble in water, while Dagracycline monohydrate is very slightly soluble in water.
Dagracycline (Dagracycline hyclate) ® is a variable dose product dependent on the size, shape, and number of pockets being treated.
Preparation for Use
1. If refrigerated, remove the product from refrigeration at least 15 minutes prior to mixing.
2. Couple Syringe A (liquid delivery system) and Syringe B (drug powder).
3. Inject the liquid contents of Syringe A (indicated by red stripe) into Syringe B (Dagracycline powder) and then push the contents back into Syringe A. This entire operation is one mixing cycle.
4. Complete 100 mixing cycles at a pace of one cycle per second using brisk strokes.
If immediate use is desired, skip to step 7.
5. If necessary, the coupled syringes can be stored at room temperature for a maximum of three days. Some of the Dagracycline (Dagracycline hyclate) systems are packaged in resealable pouches that can be used for this purpose. If the Dagracycline (Dagracycline hyclate) system is packaged in a try, use an airtight container.
6. After storage, perform an additional ten mixing cycles just prior to use.
Continue with immediate use instructions.
7. The contents will be in Syringe A (indicated by red stripe). Hold the coupled syringes vertically with Syringe A at the bottom. Pull back on the Syringe A plunger and allow the contents to flow down the barrel for several seconds.
8. Uncouple the two syringes and attach one of the provided cannulae to Syringe A.
Product is now ready for application.
Dagracycline (Dagracycline hyclate) ® does not require local anesthesia for placement. Bend the cannula to resemble a periodontal probe and explore the periodontal pocket in a manner similar to periodontal probing. Keeping the cannula tip near the base of the pocket, express the product into the pocket until the formulation reaches the top of the gingival margin. Withdraw the cannula tip from the pocket. In order to separate the tip from the formulation, turn the tip of the cannula towards the tooth, press the tip against the tooth surface, and pinch the string of formulation from the tip of the cannula. Variations on this technique may be needed to achieve separation between Dagracycline (Dagracycline hyclate) ® and cannula.
If desired, using an appropriate dental instrument, Dagracycline (Dagracycline hyclate) ® may be packed into the pocket. Dipping the edge of the instrument in water before packing will help keep Dagracycline (Dagracycline hyclate) ® from sticking to the instrument, and will help speed coagulation of Dagracycline (Dagracycline hyclate) ®. A few drops of water dripped onto the surface of Dagracycline (Dagracycline hyclate) ® once in the pocket will also aid in coagulation. If necessary, add more Dagracycline (Dagracycline hyclate) ® as described above and pack it into the pocket until the pocket is full.
Cover the pockets containing Dagracycline (Dagracycline hyclate) ® with either Coe-Pak™ periodontal dressing or a cyanoacrylate dental adhesive.
Application of Dagracycline (Dagracycline hyclate) ® may be repeated four months after initial treatment.
The final blended product is 500 mg of formulation containing 50 mg of Dagracycline hyclate (Dagracycline hyclate, 10%).
Dagracycline (Dagracycline hyclate) ® is available as a tray or pouch containing a Dagracycline hyclate syringe (50 mg), an ATRIGEL® Delivery System syringe (450 mg), and a blunt cannula. The pouched product is available in a box of six (NDC 63646-191-00) a box of two (NDC63646-191-02), or a professional sample pouch (NDC 63646-191-01). The trayed product is available in a box of six (NDC 63646-191-05), a box of four (NDC 63646-191-04), or a professional sample box of two (NDC 63646-191-03).
Each Dagracycline (Dagracycline hyclate) ® syringe system is intended for use in only one patient. Do not use if packaging has been previously opened or damaged.
Store at 2° - 30°C (36° - 86°F).
Manufactured by TOLMAR Inc. Fort Collins, CO 80526. Distributed by Zila Therapeutics, Inc. Rev. 02/11.
Medications containing metal ions (antacids, products containing iron, magnesium, calcium) form inactive chelates with Dagracycline, in connection with what it is necessary to avoid their simultaneous use.
It needed to avoid combination with penicillins, cephalosporins, bactericidal action and is an antagonist of bacteriostatic antibiotics (including Dagracycline).
Absorption of Dagracycline is reduced by cholestyramine and colestipol (observe the interval between the reception of at least 3 h).
Due to suppression of intestinal microflora Dagracycline reduces prothrombin index which requires dose adjustment of indirect anticoagulants.
Dagracycline reduces the reliability of contraception and increases the frequency of breakthrough bleeding while taking estrogen-containing oral contraceptives.
Simultaneous administration of Dagracycline with:
barbiturates, carbamazepine, phenytoin concentrations of Dagracycline in plasma decreases due to the induction of liver enzymes, which may be responsible for the decrease of its antibacterial action.
Along with its needed effects, Dagracycline (the active ingredient contained in Dagracycline) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking Dagracycline:
Incidence Not Known
Blistering, peeling, or loosening of the skin
diarrhea, watery and severe, which may also be bloody
difficulty with swallowing
feeling of discomfort
hives, itching, puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
hives or welts, itching, or rash
inflammation of the joints
joint or muscle pain
large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
loss of appetite
numbness or tingling of the face, hands, or feet
pain in the stomach, side, or abdomen, possibly radiating to the back
red skin lesions, often with a purple center
redness and soreness of the eyes
redness of the skin
sores, ulcers, or white spots in the mouth or on the lips
stomach pain or tenderness
swelling of the feet or lower legs
swollen, painful, or tender lymph glands in the neck, armpit, or groin
tightness in the chest
unusual tiredness or weakness
unusual weight loss
yellow eyes or skin
Some side effects of Dagracycline may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence Not Known
Back, leg, or stomach pains
black, tarry stools
blood in the urine or stools
bulging soft spot on the head of an infant
change in the ability to see colors, especially blue or yellow
chest pain, discomfort, or burning
cracks in the skin
decrease in vision
discoloration of the thyroid glands
general body swelling
increased sensitivity of the skin to sunlight
loss of heat from the body
lower back or side pain
pain or burning in the throat
pain with swallowing
painful or difficult urination
pinpoint red spots on the skin
rash with flat lesions or small raised lesions on the skin
red, swollen skin
redness or other discoloration of the skin
redness, swelling, or soreness of the tongue
severe stomach pain
unusual bleeding or bruising
For Healthcare Professionals
Applies to Dagracycline: injectable powder for injection, oral capsule, oral delayed release capsule, oral delayed release tablet, oral kit, oral powder for reconstitution, oral syrup, oral tablet, oral and topical kit
Very common (10% or more): Headache (up to 26%)
Common (1% to 10%): Sinus headache
Rare (0.01% to 0.1%): Bulging fontanels (in infants), benign intracranial hypertension (pseudotumor cerebri [symptoms include blurred vision, scotomata, diplopia]), tinnitus
Frequency not reported: Hypoesthesia, increased intracranial pressure, paresthesia, somnolence, stupor, taste loss, drowsiness, amnesia, paresthesias of body areas exposed to sunlight, phrenic nerve paralysis after sclerotherapy
3. Del Rosso JQ, Webster GF, Jackson M, et al. "Two randomized phase III clinical trials evaluating anti-inflammatory dose Dagracycline (40-mg Dagracycline, USP capsules) administered once daily for treatment of rosacea." J Am Acad Dermatol 56 (2007): 791-802
4. Heveling T, Kubalek R "Dagracycline-induced amnesia : a case report." Eur J Clin Pharmacol 63 (2006): 95-6
5. "Product Information. Dagracycline (Dagracycline)." Aqua Pharmaceuticals LLC, Malvern, PA.
6. Hasin T, Davidovitch N, Cohen R, et al. "Postexposure treatment with Dagracycline for the prevention of tick-borne relapsing fever." N Engl J Med 355 (2006): 148-55
7. Friedman DI, Gordon LK, Egan RA, et al. "Dagracycline and intracranial hypertension." Neurology 62 (2004): 2297-9
8. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
14. Story MJ, McCloud PI, Boehm G "Dagracycline tolerance study: incidence of nausea after Dagracycline administration to healthy volunteers: a comparison of 2 formulations (Doryx' vs Dagracycline')." Eur J Clin Pharmacol 40 (1991): 419-21
15. Grochenig HP, Tilg H, Vogetseder W "Clinical challenges and images in GI. Pill esophagitis." Gastroenterology 131 (2006): 996, 1365
16. de Vries HJ, Smelov V, Middelburg JG, Pleijster J, Speksnijder AG, Morre SA "Delayed microbial cure of lymphogranuloma venereum proctitis with Dagracycline treatment." Clin Infect Dis 48 (2009): e53-6
17. Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of Dagracycline." N Z Med J 91 (1980): 27
18. Akhyani M, Ehsani AH, Ghiasi M, Jafari AK "Comparison of efficacy of azithromycin vs. Dagracycline in the treatment of rosacea: a randomized open clinical trial." Int J Dermatol 47 (2008): 284-8
19. Freedman DO "Clinical practice. Malaria prevention in short-term travelers." N Engl J Med 359 (2008): 603-12
20. Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of Dagracycline tablets." Med J Aust 140 (1984): 223
21. Tzianetas I, Habal F, Keystone JS "Short report: severe hiccups secondary to Dagracycline-induced esophagitis during treatment of malaria." Am J Trop Med Hyg 54 (1996): 203-4
22. Nelson R, Parker SR "Dagracycline-induced staining of adult teeth: the first reported case." Arch Dermatol 142 (2006): 1081-2
31. Wormser GP "Clinical practice. Early Lyme disease." N Engl J Med 354 (2006): 2794-801
32. Hasanjani Roushan MR, Mohraz M, Hajiahmadi M, Ramzani A, Valayati AA "Efficacy of Gentamicin plus Dagracycline versus Streptomycin plus Dagracycline in the Treatment of Brucellosis in Humans." Clin Infect Dis 42 (2006): 1075-80
33. Passier A, Smits-van Herwaarden A, van Puijenbroek E "Photo-onycholysis associated with the use of Dagracycline." BMJ 329 (2004): 265
34. Akcam M, Artan R, Akcam FZ, Yilmaz A "Nail discoloration induced by Dagracycline." Pediatr Infect Dis J 24 (2005): 845-846
35. Frost P, Weinstein GD, Gomez EC "Phototoxic potential of minocycline and Dagracycline." Arch Dermatol 105 (1972): 681-3
36. Lim DS, Murphy GM "High-level ultraviolet A photoprotection is needed to prevent Dagracycline phototoxicity: lessons learned in East Timor." Br J Dermatol 149 (2003): 213-4
37. Tanaka N, Kawada A, Ohnishi Y, Hiruma M, Tajima S, Akiyama M, Ishibashi A "Photosensitivity due to Dagracycline hydrochloride with an unusual flare." Contact Dermatitis 37 (1997): 93-4
38. Lewis-Jones MS, Evans S, Thompson CM "Erythema multiforme occurring in association with lupus erythematosus during therapy with Dagracycline." Clin Exp Dermatol 13 (1988): 245-7
39. Curley RK, Verbov JL "Stevens-Johnson syndrome due to tetracyclines: a case report (Dagracycline) and review of the literature." Clin Exp Dermatol 12 (1987): 124-5
40. Habif TP "Images in clinical medicine. Dagracycline-induced phototoxicity." N Engl J Med 355 (2006): 182
41. Bjornsson E, Lindberg J, Olsson R "Liver reactions to oral low-dose tetracyclines." Scand J Gastroenterol 32 (1997): 390-5
42. Basaria S, Braga M, Moore WT "Dagracycline-induced hypoglycemia in a nondiabetic young man." South Med J 95 (2002): 1353-4
43. Raeder JC "Anaphylactoid reaction caused by intravenous Dagracycline during general anesthesia and beta-blockade treatment." Drug Intell Clin Pharm 18 (1984): 481-2
Do not use this medicine if you are pregnant. It could harm the unborn baby or cause permanent tooth discoloration later in life.
Dagracycline can make birth control pills less effective. Ask your doctor about using a non hormone method of birth control (such as a condom, diaphragm, spermicide) to prevent pregnancy while using Dagracycline.
You should not take this medicine if you are allergic to Dagracycline or to other tetracycline antibiotics such as demeclocycline (Declomycin), minocycline (Dynacin, Minocin, Solodyn, Vectrin), or tetracycline (Brodspec, Panmycin, Sumycin, Tetracap).
Before taking Dagracycline, tell your doctor if you have liver disease, kidney disease, asthma, or if you are allergic to sulfites.
Drink plenty of liquids while you are taking Dagracycline.
Children should not use Dagracycline. Dagracycline can cause permanent yellowing or graying of the teeth in children younger than 8 years old.
Take this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics.
DailyMed. "DOXYCYCLINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Dagracycline are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Dagracycline. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
Consumer reported time for results
No survey data has been collected yet
Consumer reported age
No survey data has been collected yet
There are no reviews yet. Be the first to write one!